Quick Read
EPA and DHA are two distinct omega-3 fatty acids with different jobs in your brain. DHA is physically embedded in brain cell membranes and acts as a structural material that keeps them flexible and efficient. EPA barely exists in brain tissue but works mainly in the bloodstream and peripheral tissues, generating anti-inflammatory compounds that calm immune activity. Both produce special molecules called specialised pro-resolving mediators that actively tell the immune system to stand down and repair damage, rather than just blocking inflammation.
DHA appears superior for protecting brain structure and reversing age-related inflammation in brain immune cells called microglia, while EPA has stronger evidence for mood and stress. Research on whether these supplements can prevent or reverse Alzheimer’s disease shows mixed results in human trials, partly because studies have been poorly designed, haven’t measured baseline omega-3 status, and have tested people whose disease is already advanced. Animal studies are very promising, and observational data suggests people who eat more omega-3s have better cognitive outcomes, but definitive proof in humans is still lacking.
For most people, a combined EPA and DHA supplement providing 1,000 to 2,000mg daily, taken with fatty food, is a reasonable approach. These nutrients appear most valuable as a long-term preventive strategy started in midlife rather than as a treatment for established disease. Omega-3 supplementation is safe and inexpensive but should complement, not replace, sleep, exercise, and a broadly anti-inflammatory diet.
Verdict: EPA and DHA are distinct molecules with different anti-inflammatory roles, with DHA showing stronger mechanistic evidence for brain structure and EPA for mood, but human trial evidence for reversing Alzheimer’s disease remains inconsistent and inconclusive.
EPA vs DHA: The Complete Biochemical Split for Neuro-Inflammation
You’ve probably seen fish oil supplements listed with two numbers on the label, EPA and DHA, and assumed they were essentially the same thing in slightly different packaging. Most people do. Even many healthcare professionals treat them as interchangeable, recommending “omega-3s” as a single, unified nutrient. But here’s the thing: EPA and DHA are genuinely distinct molecules, with different jobs in your brain, different anti-inflammatory mechanisms, and different clinical effects. What if the reason some omega-3 trials fail isn’t that omega-3s don’t work, but that researchers have been using the wrong one, in the wrong ratio, for the wrong purpose?
This is one of the most important distinctions in brain health nutrition, and it’s one that almost nobody is talking about clearly. At Vitacuity, we’ve analysed over 1.77 million research papers and selected the most relevant findings on this topic. What follows is the clearest, most honest breakdown we can offer of what the science actually says about EPA versus DHA, where they overlap, where they diverge, and what that means for your brain as you age.
The Science Behind EPA and DHA: Same Family, Very Different Lives
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are both long-chain omega-3 polyunsaturated fatty acids (PUFAs), and they both come primarily from marine sources, oily fish, algae, and high-quality supplements. But their roles in the brain are remarkably different.
DHA is the dominant omega-3 fatty acid in the brain itself. It’s physically woven into the structure of nerve cell membranes, particularly in the phospholipids that form the outer layer of neurons [1]. Think of it as a structural material: DHA keeps membranes fluid and flexible, which is essential for the speed and efficiency of communication between brain cells. It’s particularly concentrated in the synapses, the junctions where one neuron talks to another, and it’s critical for synaptic plasticity, the brain’s ability to strengthen or weaken connections in response to experience [4].
EPA, on the other hand, is barely detectable in brain tissue despite being highly active in the bloodstream and peripheral tissues [3]. This puzzled researchers for years, why would a molecule with such clear brain benefits be almost absent from the organ it’s supposed to help? The answer appears to lie in what EPA does *before* it reaches the brain, and in the specialised signalling molecules it produces along the way.
Both EPA and DHA are metabolised into a class of bioactive compounds called oxylipins, which include the celebrated specialised pro-resolving mediators (SPMs): resolvins, protectins, and maresins [6]. These aren’t just anti-inflammatory signals. They actively resolve inflammation, meaning they instruct the immune system to *stand down* and repair tissue, rather than simply blocking the inflammatory signal in the first place. This is a critical distinction. Most anti-inflammatory drugs work by suppression. EPA and DHA work, in part, by resolution, a fundamentally more sophisticated biological process [13].
Where EPA and DHA diverge is in *which* SPMs they produce and *where* they act. EPA preferentially generates resolvins of the E-series and feeds into the cytochrome P450 (CYP) monooxygenase pathway, producing unique eicosanoids not generated by DHA [15]. DHA generates resolvins of the D-series, neuroprotectins, and maresins, molecules with particular relevance to brain tissue repair and neuronal survival [4][6]. These are not minor biochemical footnotes. They represent genuinely different biological languages for controlling inflammation.
DHA: The Brain’s Structural Architect and Inflammation Resolver
Evidence grade: Promising to strong for mechanism; promising for clinical outcomes
DHA is to your brain what reinforced concrete is to a building, it provides the structural integrity that everything else depends on. At roughly 10–15% of the brain’s total fatty acid content, DHA is embedded in neuronal membranes at concentrations that influence how those membranes function at a fundamental level [1][4].
Here’s why that matters for inflammation. Within neuronal membranes, DHA clusters into specialised microdomains called lipid rafts, platforms that organise and regulate cell signalling. When DHA remodels these rafts, it changes which inflammatory signals can be transmitted. Specifically, it attenuates the activation of two key inflammatory engines: NF-κB (nuclear factor kappa B, a master regulator of the inflammatory response) and the NLRP3 inflammasome (a molecular complex that triggers the release of potent pro-inflammatory cytokines) [4]. In plain English: DHA physically rearranges the scaffolding of your brain cells in a way that makes it harder for inflammation to get started.
A 2023 animal study published on PubMed directly compared DHA and EPA in ageing rats [11]. Both omega-3s improved spatial memory compared to controls. But DHA outperformed EPA across several key neuroinflammatory markers. DHA more powerfully reversed the imbalance between pro-inflammatory (M1) and anti-inflammatory (M2) microglial states, the brain’s resident immune cells. It was more effective at restoring CD206 expression (a marker of anti-inflammatory microglia) and more potent at suppressing pro-inflammatory cytokines TNF-α, IL-1β, and IL-6, while EPA only significantly reduced IL-6. DHA also more powerfully regulated astrocyte polarisation, the activation state of the brain’s support cells, compared to EPA [11].
A 2026 narrative review in Histology and Histopathology synthesised evidence from mechanistic studies, clinical trials, and meta-analyses, proposing a “systems-level model” in which DHA integrates structural, bioenergetic, and immune-resolution domains to govern neuroinflammatory homeostasis [4]. This review highlights that DHA also enhances mitochondrial bioenergetics and redox homeostasis, meaning it supports the energy production of brain cells while reducing the oxidative stress that contributes to neuronal damage over time.
The clinical picture for DHA in Alzheimer’s disease is more complicated, and we’ll address that honestly below. But at the mechanistic level, the evidence for DHA as the brain’s primary structural and neuroinflammatory regulator is compelling [5].
EPA: The Peripheral Firefighter With a Surprising Reach
Evidence grade: Promising for inflammation resolution and mood; early stage for direct brain mechanisms
EPA’s near-absence from brain tissue creates what researchers have called the “EPA paradox” [15]. If EPA is so active in fighting inflammation, and if neuroinflammation is so central to brain ageing and disease, why doesn’t EPA accumulate in the brain the way DHA does?
The emerging answer is that EPA may work largely *outside* the brain, in the bloodstream, the gut, and peripheral immune tissues, generating a cascade of anti-inflammatory signals that then propagate inward [3][15]. EPA is the primary precursor to 18-HEPE, a specialised pro-resolving mediator precursor that initiates the production of E-series resolvins. These molecules actively resolve inflammation in peripheral tissues, reducing the overall inflammatory burden that the brain is exposed to.
A 2026 meta-analysis of 11 randomised controlled trials (810 participants total) measured the effect of omega-3 supplementation on circulating SPM precursors [3]. The findings were striking: omega-3 supplementation significantly raised blood levels of both 18-HEPE (the EPA-derived SPM precursor) and 17-HDHA (the DHA-derived SPM precursor). The effect sizes were meaningful, standardised mean difference of 1.05 for 18-HEPE and 0.69 for 17-HDHA. Crucially, these increases were most pronounced in populations carrying the highest inflammatory burden: people with peripheral artery disease, chronic kidney disease, obesity with depression, and pregnancy. In healthy infants, the increase was negligible. This suggests EPA’s resolving effects are most active when inflammation is already elevated, which, for most people over 50, is exactly the situation [3].
EPA also competes directly with arachidonic acid (AA), the omega-6 fatty acid that is the primary driver of pro-inflammatory eicosanoid production. EPA and AA compete for the same enzymes (COX and LOX pathways), so when EPA levels rise, AA-derived pro-inflammatory metabolites fall [15][6]. This is one reason that the omega-3 to omega-6 ratio in your diet matters so much, it’s not just about adding omega-3s, it’s about shifting the competitive balance.
There’s also the mood connection. Multiple meta-analyses (referenced across our source papers) have found that EPA-dominant omega-3 preparations outperform DHA-dominant ones for depression and mood disorders [6][15]. A 2021 review in the International Journal of Molecular Sciences systematically examined the biochemical reasons for this, pointing to EPA’s preferential activity through the CYP monooxygenase pathway, its unique CB2 cannabinoid receptor-active metabolites (EPEA and 17,18-EEQ-EA), and its competition with arachidonic acid in phosphatidylinositol, a lipid class with direct relevance to mood signalling [15]. DHA-derived endocannabinoids, by contrast, lack these specific CB2 receptor affinities [15].
The Endocannabinoid Connection: A Shared Pathway You Didn’t Know About
Evidence grade: Early stage, primarily mechanistic and animal data
Here’s something that doesn’t get nearly enough attention: both EPA and DHA interact with the endocannabinoid system, the same system targeted by cannabis compounds, and one deeply involved in mood, pain, neuroinflammation, synaptic plasticity, and neurogenesis [10].
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the brain’s own endocannabinoids, both derived from arachidonic acid. When you supplement with omega-3s long-term, something interesting happens: EPA and DHA supplementation reduces circulating levels of AEA and 2-AG, while simultaneously increasing levels of analogous DHA- and EPA-derived “endocannabinoid-like” molecules [10]. These novel molecules, DHEA (docosahexaenoyl ethanolamide) and EPEA (eicosapentaenoyl ethanolamide), appear to interact with cannabinoid receptors, though with different affinities to the arachidonic acid-derived originals.
A 2017 review in Lipids synthesised the current evidence for this interplay, noting that omega-3 enrichment of the diet effectively shifts the endocannabinoid system toward less pro-inflammatory signalling [10]. EPEA, the EPA-derived endocannabinoid-like molecule, has demonstrated affinity for CB2 receptors, the cannabinoid receptors most associated with immune modulation and anti-inflammatory effects in the brain [15]. This may partially explain EPA’s outsized effect on mood and neuroinflammation despite its physical absence from brain tissue.
This is early-stage science, most of the evidence is mechanistic or from animal studies, but it represents one of the most intellectually exciting frontiers in nutritional neuroscience.
Microglial Polarisation: How EPA and DHA Calm Your Brain’s Immune Cells
Evidence grade: Promising, animal data with supporting mechanistic human evidence
Your brain has its own immune system, centred on specialised cells called microglia. In a healthy brain, microglia exist in a surveillant, anti-inflammatory state (sometimes called M2). When they detect damage, infection, or misfolded proteins, they switch to a pro-inflammatory, activated state (M1). This switch is essential for short-term defence, but when it becomes chronic, as it does during ageing and neurodegeneration, it drives sustained neuroinflammation that damages neurons and impairs cognition [11][13].
The 2023 ageing rat study [11] directly examined how DHA and EPA influence this microglial polarisation balance. In aged rats (which show the same M1/M2 imbalance seen in human brain ageing), both DHA and EPA treatment reversed the inflammatory shift, reducing IBA1 (a marker of microglial activation) and restoring anti-inflammatory markers CD206 and ARG-1 in the hippocampus. DHA was consistently more effective at restoring the M2 (anti-inflammatory) phenotype.
A 2018 review in Pharmacological Reviews [13] expanded on these mechanisms, explaining how DHA’s metabolites, particularly neuroprotectin D1 (NPD1), derived from DHA via 15-lipoxygenase, directly suppress microglial activation and promote the resolution of neuroinflammation. The review also noted that the brain’s lipid metabolism is highly sensitive to diet, sex, genetics, and ageing, all of which influence how effectively omega-3s reach and reshape microglial function. This context-dependence is part of why clinical trials show such variable results.
Alzheimer’s Disease: What the Evidence Actually Shows
Evidence grade: Conflicted, strong mechanistic rationale, inconsistent clinical trial results
This is where we need to be genuinely honest with you, because the story is more complicated than supplement marketing would suggest.
In animal models, DHA and EPA supplementation reduces amyloid-β (Aβ) deposition, modulates microglial activation, and prevents cognitive decline [1][9]. These findings are consistent and biologically plausible. The problem is that animal models of Alzheimer’s disease don’t translate perfectly to human disease, and the clinical trial record reflects this.
Observational studies in humans generally show that people with higher omega-3 intake or higher blood levels of DHA and EPA have better cognitive outcomes and lower rates of Alzheimer’s disease [12]. But observational studies can’t prove causation, people who eat more fish also tend to have healthier diets and lifestyles overall [5].
Randomised controlled trials, the gold standard, have produced inconsistent results, and the 2025 review in Progress in Lipid Research [12] offers one of the clearest analyses of why. It’s not that omega-3s don’t work. It’s that most trials have been poorly designed for omega-3 research specifically. Problems include: testing people who already have established Alzheimer’s disease (when neuronal loss may be too advanced for omega-3s to reverse), failing to measure baseline omega-3 status (supplementing people who are already replete yields smaller effects), not accounting for APOE ε4 genotype (which affects how DHA is transported to the brain), using varying doses and chemical forms, and using inadequate placebo oils that are themselves biologically active [12].
A 2026 review in Pharmacological Research [5] makes the same point: individuals with early, potentially modifiable pathology, combined with sufficient cerebral DHA availability, appear most likely to benefit. The window of opportunity matters enormously.
Similarly, a 2026 review in European Journal of Pharmacology [2][14] concluded that while DHA and EPA are “biologically plausible neuropharmacological modulators,” current evidence does not establish them as broadly effective disease-modifying treatments for established neurodegenerative diseases. The emphasis is on *established*, the case for prevention and early intervention remains genuinely open.
The honest summary: omega-3s, and DHA in particular, have a compelling mechanistic case for protecting the brain against neuroinflammation. The clinical trial evidence for *reversing* established Alzheimer’s disease is weak and inconsistent. The case for *prevention*, especially in midlife, before pathology has accumulated, is biologically plausible and supported by observational data, but not yet proven in long-term RCTs.
Beyond Alzheimer’s: EPA, DHA and the Broader Neurodegenerative Picture
Evidence grade: Early stage to promising, mechanistic and observational data, limited RCT evidence
The 2023 review in the International Journal of Molecular Sciences [7] examined omega-3 evidence across multiple neurodegenerative conditions: Parkinson’s disease, multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis (ALS). In each case, the mechanistic rationale is similar, chronic neuroinflammation is a central feature, and EPA/DHA have established anti-inflammatory and pro-resolving mechanisms. The clinical trial record across these conditions is thin, with small samples and short durations. The dosages used in clinical studies have varied widely, making comparison difficult.
One consistent theme across the literature: neuroinflammation is not a single uniform process. It involves microglia, astrocytes, the blood-brain barrier, mitochondrial function, and the gut-brain axis, and DHA and EPA appear to influence all of these systems, though to different degrees and through different mechanisms [1][4]. The idea that a single nutrient, or a single omega-3, could comprehensively address the full complexity of neurodegeneration is probably unrealistic. But that doesn’t mean these molecules aren’t genuinely valuable components of a broader protective strategy.
What We Don’t Know Yet
Let’s be direct about the gaps, because there are significant ones.
Brain bioavailability is poorly understood. EPA barely appears in brain tissue despite being active in the blood. DHA does reach the brain, but how efficiently it crosses the blood-brain barrier varies by age, genetics (particularly APOE genotype), metabolic health, and formulation. Most clinical trials have never actually measured whether their intervention changed DHA levels in the brain, they’ve measured blood levels as a proxy [2][14].
We don’t know the optimal dose or ratio. Most supplements combine EPA and DHA, often at a 3:2 or 2:1 EPA:DHA ratio. But the research suggests EPA and DHA have distinct roles, so what ratio is best depends on what you’re trying to achieve (mood vs. structural brain protection, for example). Very few trials have systematically compared different ratios [12].
Timing matters enormously, and we don’t have good data on it. The evidence suggests omega-3s work best as a preventive strategy, started early, possibly in midlife. But there are no large, long-term RCTs starting supplementation in healthy 40-year-olds and tracking them for 20 years. The trials we have are mostly too short and in populations who are already cognitively impaired [5][12].
Genetics complicate everything. APOE ε4 carriers, who have elevated genetic risk for Alzheimer’s disease, appear to have altered DHA transport and metabolism. Some trials show that APOE ε4 carriers respond differently to DHA supplementation than non-carriers. We don’t yet know whether this means they need more DHA, less, or a different form [5][12].
The SPM precursor story is incomplete. The 2026 meta-analysis [3] confirmed that omega-3 supplementation raises circulating SPM precursors, but whether this translates into increased actual SPM production in the brain, and whether that translates into measurable clinical benefit, remains unproven. These are different steps in a chain, and we’ve only confirmed the first link.
The chemical form of omega-3 supplements matters. Triglyceride-form omega-3s are absorbed differently from ethyl ester forms, and lysophosphatidylcholine-bound DHA (found in some krill-based products) may cross the blood-brain barrier more efficiently. Very few trials have systematically compared these forms [12].
The Final Takeaway
So what does a sensible, informed person actually do with all of this?
First, understand what you’re optimising for. If you’re in your 40s or 50s, the most important thing you can do is build and maintain your brain’s DHA reserves, because DHA is the structural material of your neurons, and those reserves decline with age. Think of this as long-term maintenance, not acute treatment.
If mood, stress resilience, or low-grade inflammation are your primary concerns, an EPA-dominant supplement (at least 60% EPA) has the stronger evidence base for those outcomes [6][15]. If your focus is structural brain protection and long-term neuroprotection against cognitive decline, DHA-rich preparations have the stronger biological rationale [1][4][11].
The good news is that most high-quality fish oil supplements contain both, and given the evidence, there’s no compelling reason to choose exclusively one or the other. A combined EPA+DHA supplement providing 1,000–2,000mg of combined EPA and DHA daily is a reasonable starting point for most people, consistent with doses used across the clinical literature [7].
On supplementing vs. testing first: Omega-3 testing exists (the Omega-3 Index blood test measures EPA+DHA as a percentage of red blood cell fatty acids), and if you’re genuinely curious about your status, it’s worth doing. But testing isn’t essential before you start. Omega-3 deficiency is common in populations eating Western diets, particularly those who don’t eat oily fish at least twice a week. The supplement is safe, inexpensive relative to other interventions, and the risk-benefit calculation strongly favours supplementing rather than waiting. This is not a nutrient where excess at normal supplement doses poses a meaningful risk.
Take it with your fattiest meal of the day. EPA and DHA are fat-soluble, absorption improves significantly when taken alongside dietary fat. This is a simple, free optimisation that many people miss.
Consistency over dose. The evidence suggests that long-term, sustained intake matters more than any individual dose. This isn’t a supplement you take for a month and evaluate. Think in terms of years, not weeks.
Don’t expect miracles from omega-3s alone. The research is clear that these are modulatory nutrients, they shift biology in a favourable direction, they don’t override it. Sleep, exercise, social connection, and a broadly anti-inflammatory diet (the Mediterranean diet has the strongest evidence base here, partly *because* it’s rich in omega-3s) remain the primary pillars of brain health. Omega-3 supplementation is a genuinely valuable addition to those foundations, not a replacement for them.
One final thought: the reason clinical trials have produced inconsistent results isn’t that EPA and DHA are ineffective. It’s that we’ve been asking them to reverse advanced disease in short trials without measuring baseline status or brain bioavailability. The more relevant question for most people reading this isn’t “can omega-3s cure Alzheimer’s?”, it’s “can a consistent, decades-long habit of maintaining adequate EPA and DHA reduce my risk of getting there?” The observational evidence says yes. The mechanistic evidence says yes. We’re still waiting for the definitive RCT to say yes. In the meantime, the risk of supplementing is low and the potential upside is significant.
References
[1] Omega-3 Fatty Acids and Alzheimer’s Disease: Toward a New Understanding of Neuroprotective Mechanisms and Intervention Strategies (2026). DOI: 10.3390/md24070224 | https://pubmed.ncbi.nlm.nih.gov/42505964/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13413024/
[2] Neuropharmacology of omega-3 long-chain polyunsaturated fatty acids in neurodegenerative diseases: mechanisms, multi-omics evidence, and clinical translation (2026). DOI: 10.1007/s00210-026-06086-y | https://pubmed.ncbi.nlm.nih.gov/43033255/
[3] Omega-3 fatty acids, specialized pro-resolving mediators, and depression: A mechanistic meta-analysis of precursors and clinical implications (2026). DOI: 10.1016/j.bbi.2026.106922 | https://pubmed.ncbi.nlm.nih.gov/42520986/
[4] DHA as a systems regulator of neuroinflammation: A narrative review integrating membrane organization, immunometabolism, and inflammatory resolution (2026). DOI: 10.14670/HH-25-155 | https://pubmed.ncbi.nlm.nih.gov/42885338/
[5] DHA in Alzheimer’s disease: The translational gap between mechanistic complexity and clinical inconsistency (2026). DOI: 10.1016/j.phrs.2026.108479 | https://pubmed.ncbi.nlm.nih.gov/42785536/
[6] Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease (2016). DOI: 10.3945/an.116.012187 | https://pubmed.ncbi.nlm.nih.gov/27633106/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015035/
[7] DHA/EPA (Omega-3) and LA/GLA (Omega-6) as Bioactive Molecules in Neurodegenerative Diseases (2023). DOI: 10.3390/ijms241310717 | https://pubmed.ncbi.nlm.nih.gov/37445890/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341783/
[8] Strategic delivery of omega-3 fatty acids for modulating inflammatory neurodegenerative diseases (2025). https://pubmed.ncbi.nlm.nih.gov/40166615/
[9] Omega-3 Fatty Acids and Alzheimer’s Disease: Toward a New Understanding of Neuroprotective Mechanisms and Intervention Strategies (2026). DOI: 10.3390/md24070224 | https://pubmed.ncbi.nlm.nih.gov/42505964/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13413024/
[10] Interplay Between n-3 and n-6 Long-Chain Polyunsaturated Fatty Acids and the Endocannabinoid System in Brain Protection and Repair (2017). DOI: 10.1007/s11745-017-4292-8 | https://pubmed.ncbi.nlm.nih.gov/28875399/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656721/
[11] Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid or Docosahexaenoic Acid Improved Ageing-Associated Cognitive Decline by Regulating Glial Polarization (2023). https://pubmed.ncbi.nlm.nih.gov/37504929/
[12] Omega-3 polyunsaturated fatty acids in neurodegenerative disorders: Mixed designs = mixed results (2025). DOI: 10.1016/j.plipres.2025.101356 | https://pubmed.ncbi.nlm.nih.gov/40976313/
[13] Anti-Inflammatory Effects of Omega-3 Fatty Acids in the Brain: Physiological Mechanisms and Relevance to Pharmacology (2018). DOI: 10.1124/pr.117.014092 | https://pubmed.ncbi.nlm.nih.gov/29217656/
[14] Neuropharmacology of omega-3 long-chain polyunsaturated fatty acids in neurodegenerative diseases: mechanisms, multi-omics evidence, and clinical translation (2026). DOI: 10.1007/s00210-026-06086-y | https://pubmed.ncbi.nlm.nih.gov/43033255/
[15] Disentangling the Molecular Mechanisms of the Antidepressant Activity of Omega-3 Polyunsaturated Fatty Acid: A Comprehensive Review of the Literature (2021). DOI: 10.3390/ijms22094393 | https://pubmed.ncbi.nlm.nih.gov/33922396/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122828/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.